Use of 2-[18F]fluoro-2-deoxyglucose as a potential agent in the prediction of graft rejection by positron emission tomography

Transplantation. 1998 Oct 27;66(8):1101-3. doi: 10.1097/00007890-199810270-00022.

Abstract

Background: We investigated the potential of predicting allograft rejection by measuring the ability of graft-infiltrating cells to take up 2-[18F]fluoro-2-deoxyglucose ([18F]FDG). This molecule is a positron emitting glucose analogue that is taken up by metabolically active cells and can be detected using positron emission tomography.

Methods: Uptake of [18F]FDG during an alloresponse was measured both in vitro in mixed lymphocyte cultures and in vivo using allogeneic and syngeneic skin grafts.

Results: Uptake of [18F]FDG was seen in a mixed lymphocyte reaction. Using a mouse skin graft model, we found that mean [18F]FDG uptake was 1.5-2 times higher in allografts than in syngeneic grafts; the increase in uptake correlated with the level of T-cell infiltrate seen histologically.

Conclusion: Assessing the metabolic activity of graft-infiltrating cells with [18F]FDG may be useful in the prediction of graft rejection episodes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Fluorodeoxyglucose F18 / pharmacokinetics*
  • Forecasting
  • Graft Rejection / diagnostic imaging*
  • Graft Rejection / metabolism*
  • Lymphocyte Culture Test, Mixed
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred CBA
  • Radiopharmaceuticals / pharmacokinetics*
  • Skin Transplantation*
  • Tomography, Emission-Computed*
  • Transplantation, Homologous
  • Transplantation, Isogeneic

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18